STOCK TITAN

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Sonnet BioTherapeutics (NASDAQ: SONN) has released a Virtual Investor segment featuring CEO Dr. Pankaj Mohan and CSO Dr. John Cini discussing their recent U.S. patent issuance. The patent covers a variant of IL-18 incorporated into two novel immunotherapeutic drug candidates: SON-1400 (IL-18BPR-FHAB) and SON-1411 (IL-18BPR-FHAB-IL12). Both candidates contain a modified version of recombinant human interleukin-18 (IL-18BPR = Binding Protein Resistant).

Sonnet BioTherapeutics (NASDAQ: SONN) ha rilasciato un segmento Virtual Investor con il CEO Dr. Pankaj Mohan e il CSO Dr. John Cini che discutono la recente emissione di brevetto negli Stati Uniti. Il brevetto copre una variante di IL-18 incorporata in due nuovi candidati farmaci immunoterapici: SON-1400 (IL-18BPR-FHAB) e SON-1411 (IL-18BPR-FHAB-IL12). Entrambi i candidati contengono una versione modificata dell'interleuchina-18 umana ricombinante (IL-18BPR = Binding Protein Resistant).

Sonnet BioTherapeutics (NASDAQ: SONN) ha lanzado un segmento de Inversor Virtual con el CEO Dr. Pankaj Mohan y el CSO Dr. John Cini discutiendo su reciente emisión de patente en EE. UU.. La patente cubre una variante de IL-18 incorporada en dos nuevos candidatos a medicamentos inmunoterapéuticos: SON-1400 (IL-18BPR-FHAB) y SON-1411 (IL-18BPR-FHAB-IL12). Ambos candidatos contienen una versión modificada de interleucina-18 humana recombinante (IL-18BPR = Binding Protein Resistant).

Sonnet BioTherapeutics (NASDAQ: SONN)가 CEO Dr. Pankaj Mohan과 CSO Dr. John Cini가 최근 미국 특허 발급에 대해 논의하는 Virtual Investor 세그먼트를 발표했습니다. 이 특허는 두 개의 새로운 면역치료제 후보인 SON-1400 (IL-18BPR-FHAB)과 SON-1411 (IL-18BPR-FHAB-IL12) 내부에 포함된 IL-18의 변형을 다룹니다. 두 후보 모두 변형된 재조합 인간 인터루킨-18 (IL-18BPR = Binding Protein Resistant)을 포함하고 있습니다.

Sonnet BioTherapeutics (NASDAQ: SONN) a publié un segment Virtual Investor avec le PDG Dr. Pankaj Mohan et le CSO Dr. John Cini discutant de leur récente octroi de brevet aux États-Unis. Le brevet couvre une variante d'IL-18 intégrée dans deux nouveaux candidats médicaments immunothérapeutiques : SON-1400 (IL-18BPR-FHAB) et SON-1411 (IL-18BPR-FHAB-IL12). Les deux candidats contiennent une version modifiée de l'interleukine-18 humaine recombinante (IL-18BPR = Binding Protein Resistant).

Sonnet BioTherapeutics (NASDAQ: SONN) hat ein Virtual Investor Segment veröffentlicht, in dem CEO Dr. Pankaj Mohan und CSO Dr. John Cini über ihre kürzliche Patenterteilung in den USA diskutieren. Das Patent umfasst eine Variante von IL-18, die in zwei neuen immuntherapeutischen Medikamentenkandidaten eingebaut ist: SON-1400 (IL-18BPR-FHAB) und SON-1411 (IL-18BPR-FHAB-IL12). Beide Kandidaten enthalten eine modifizierte Version des rekombinanten menschlichen Interleukin-18 (IL-18BPR = Binding Protein Resistant).

Positive
  • Secured U.S. patent protection for IL-18 variant technology
  • Patent covers two novel drug candidates in development pipeline
Negative
  • None.

Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic drug candidates, SON-1400 and SON-1411

Watch the “What this Means” segment here

PRINCETON, NJ, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted immunotherapeutic drugs, today announced that Pankaj Mohan, PhD, Chief Executive Officer of Sonnet, and John Cini, PhD, Chief Scientific Officer of Sonnet, participated in a Virtual Investor “What this Means” segment released by Sonnet.

As part of the segment, Drs. Mohan and Cini discussed the recent U.S. Patent titled, “Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same,” covering two of its novel drug candidates, SON-1411 (IL-18BPR-FHAB-IL12) and SON-1400 (IL-18BPR-FHAB), each containing a modified version of recombinant human interleukin-18 (IL-18BPR = Binding Protein Resistant).

The Virtual Investor “What this Means” segment featuring Sonnet is now available here.

About Sonnet

Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB platform is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the outcome of the Company’s clinical trials, the Company's cash runway, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or the Company's financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include market conditions and the satisfaction of customary closing conditions related to the offering and those set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
908-824-0775
SONN@jtcir.com


FAQ

What patent did Sonnet BioTherapeutics (SONN) recently receive?

Sonnet recently received a U.S. patent titled 'Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same,' covering their drug candidates SON-1411 and SON-1400.

What are the two drug candidates covered by Sonnet's (SONN) new patent?

The patent covers SON-1411 (IL-18BPR-FHAB-IL12) and SON-1400 (IL-18BPR-FHAB), both containing a modified version of recombinant human interleukin-18.

What technology does Sonnet's (SONN) new patent protect?

The patent protects a variant of IL-18 (IL-18BPR = Binding Protein Resistant) incorporated into two immunotherapeutic drug candidates.

Sonnet BioTherapeutics Holdings, Inc.

NASDAQ:SONN

SONN Rankings

SONN Latest News

SONN Stock Data

2.37M
680.00k
4.22%
10.85%
3.21%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PRINCETON